Bicara Therapeutics Inc. (BCAX)

Bicara Therapeutics' stock price increased by 82.64% from May 6, 2025, to May 5, 2026. The company reported Q3 2025 and Q4 2025 earnings. They announced and closed an oversubscribed public offering of common stock in February 2026. Insider selling activity by the Chief Medical Officer and CEO occurred in April 2026 under pre-arranged Rule 10b5-1 trading plans.

As a clinical-stage biopharmaceutical company, Bicara Therapeutics does not experience traditional demand seasonality. The company's progress is driven by clinical trial outcomes, regulatory milestones, and investor interest.

Bicara Therapeutics, Inc. (BCAX) is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors. Their lead product candidate, ficerafusp alfa, combines an EGFR-directed monoclonal antibody with a TGF-β binding domain to block cancer cell survival and immunosuppressive signaling. Ficerafusp alfa is initially being developed for head and neck squamous cell carcinoma (HNSCC) and has received Breakthrough Therapy Designation from the FDA in combination with pembrolizumab for certain HNSCC patients.

Bicara Therapeutics, Inc. is headquartered in Boston, Massachusetts, United States.

Bicara Therapeutics has maintained a positive brand reputation, with a consensus recommendation of "Moderate Buy" and an average twelve-month target price of $28.00. Positive clinical trial data from the Phase 1/1b trial of ficerafusp alfa and the FDA's Breakthrough Therapy Designation have contributed to this reputation. No specific negative events affecting the brand reputation were found.

Bicara Therapeutics Inc. has 142 institutional owners and shareholders holding a total of 55,507,511 shares. Major institutional shareholders include Ra Capital Management, L.P., Siren, L.L.C., Vestal Point Capital, LP, Fmr Llc, Red Tree Management, LLC, Tpg Gp A, Llc, Janus Henderson Group Plc, Deep Track Capital, LP, BlackRock, Inc., and Omega Fund Management, LLC. The ownership structure includes institutional, retail, and individual investors, with a mix of ownership percentages.